董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Javier J. Rodriguez | 男 | Director and Chief Executive Officer | 54 | 2180.75万美元 | 83.78 | 2025-06-05 |
| Barbara J. Desoer | 女 | Independent Director | 72 | 38.47万美元 | 1.23 | 2025-06-05 |
| Jason M. Hollar | 男 | Independent Director | 52 | 37.22万美元 | 0.49 | 2025-06-05 |
| Phyllis R. Yale | 女 | Independent Director | 67 | 37.47万美元 | 1.29 | 2025-06-05 |
| Gregory J. Moore | 男 | Independent Director | 60 | 37.72万美元 | 0.61 | 2025-06-05 |
| Wendy L. Schoppert | 女 | Independent Director | 58 | 33.47万美元 | 0.22 | 2025-06-05 |
| Dennis W. Pullin | 男 | Independent Director | 65 | 17.25万美元 | 0.10 | 2025-06-05 |
| Pamela M. Arway | 女 | Independent Director,Board Chair | 71 | 49.97万美元 | 2.52 | 2025-06-05 |
| Adam H. Schechter | 男 | Independent Director | 60 | 33.47万美元 | 0.40 | 2025-06-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Javier J. Rodriguez | 男 | Director and Chief Executive Officer | 54 | 2180.75万美元 | 83.78 | 2025-06-05 |
| Kathleen A. Waters | 女 | Chief Legal and Public Affairs Officer | 57 | 465.14万美元 | 7.15 | 2025-06-05 |
| James O. Hearty | 男 | Chief Compliance Officer | 56 | 233.69万美元 | 1.91 | 2025-06-05 |
| Christopher Berry | 男 | Chief Accounting Officer | 50 | 未披露 | 未持股 | 2025-06-05 |
| David P. Maughan | 男 | Chief Operating Officer, DaVita Kidney Care | 48 | 493.31万美元 | 2.06 | 2025-06-05 |
| Joel Ackerman | 男 | Chief Financial Officer and Treasurer | 59 | 634.96万美元 | 11.97 | 2025-06-05 |
董事简历
中英对照 | 中文 | 英文- Javier J. Rodriguez
-
Javier J. Rodriguez，曾担任Davita Inc.的董事。自2019年6月起担任首席执行官。从2014年3月到2019年6月，他担任DaVita Kidney Care的首席执行官。自1998年加入公司以来，他曾担任多个不同的职务。2012年2月至2014年3月，他担任Davita Inc.的董事。从2006年4月到2012年2月，他担任Davita Inc.的董事，高级副总裁。从2000年到2006年，他担任运营和付款合同副总裁。Rodriguez先生于1998年加入公司，担任价值管理董事。在加入公司之前，他从1995年到1996年在Baxter Healthcare Corporation的财务部门工作。他还曾担任Mexico City CBS Marketing Inc.的运营总监。自2020年6月以来，Rodriguez先生一直是Gilead Sciences, Inc.（一家研究型制药公司）的董事会成员。
Javier J. Rodriguez,joined Board in June 2020.Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout 12 countries.He assumed his current role in 2019, building on his more than 20 years of increasing company leadership and commitment to transforming care delivery to improve quality of life for patients with kidney disease – from the earliest stages through transplantation.From 2014 to 2019, he was the CEO of DaVita Kidney Care, the company's business unit that treats patients with kidney failure and end-stage kidney disease.Mr. Rodriguez is recognized for his vision and leadership in transforming how kidney care is delivered and accelerating the digital transformation to improve patients' lives while lowering costs for the health care system.He currently serves on the board of directors of DaVita, Inc. - Javier J. Rodriguez，曾担任Davita Inc.的董事。自2019年6月起担任首席执行官。从2014年3月到2019年6月，他担任DaVita Kidney Care的首席执行官。自1998年加入公司以来，他曾担任多个不同的职务。2012年2月至2014年3月，他担任Davita Inc.的董事。从2006年4月到2012年2月，他担任Davita Inc.的董事，高级副总裁。从2000年到2006年，他担任运营和付款合同副总裁。Rodriguez先生于1998年加入公司，担任价值管理董事。在加入公司之前，他从1995年到1996年在Baxter Healthcare Corporation的财务部门工作。他还曾担任Mexico City CBS Marketing Inc.的运营总监。自2020年6月以来，Rodriguez先生一直是Gilead Sciences, Inc.（一家研究型制药公司）的董事会成员。
- Javier J. Rodriguez,joined Board in June 2020.Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout 12 countries.He assumed his current role in 2019, building on his more than 20 years of increasing company leadership and commitment to transforming care delivery to improve quality of life for patients with kidney disease – from the earliest stages through transplantation.From 2014 to 2019, he was the CEO of DaVita Kidney Care, the company's business unit that treats patients with kidney failure and end-stage kidney disease.Mr. Rodriguez is recognized for his vision and leadership in transforming how kidney care is delivered and accelerating the digital transformation to improve patients' lives while lowering costs for the health care system.He currently serves on the board of directors of DaVita, Inc.
- Barbara J. Desoer
-
Barbara J. Desoer，自2015年10月起担任公司董事。Desoer现任Citibank, N.A（Citigroup Inc. 一家全资子公司，一家多元全球金融服务公司）首席执行官和董事，自2014年4月起担任该职位。Desoer之前从2013年10月到2014年4月担任Citibank, N.A首席运营官。除了担任首席执行官之外，Desoer还领导Citigroup的综合资本分析和评估过程。加入Citibank之前，Desoer在Bank of America（一家多元全球金融服务公司）任职了35年，最近的职位是担任Bank of America Home Loans总裁，领导Countrywide（美国最大的抵押贷款发起人和服务商）的整合。在Bank of America任职之前，Desoer担任全球技术&运营主管（一个国际市场支持职位，领导英国、亚洲和拉丁美洲的小组）。她还曾担任消费产品总裁。她现任the California大学at Berkeley客座董事。Desoer还曾担任多个非盈利和私人控股公司董事。
Barbara J. Desoer,served as the CEO and a member of the Board of Directors of Citibank, N.A., a wholly owned subsidiary of Citigroup, Inc., a diversified global financial services company, both positions she held from April 2014 through April 2019, and COO of Citibank, N.A. from October 2013 to April 2014. Prior to Citibank, N.A., Ms. Desoer spent 35 years at Bank of America, a diversified global financial services company, most recently as President, Bank of America Home Loans, where she led the integration of Countrywide, the largest mortgage originator and servicer in the United States. In previous Bank of America roles, Ms. Desoer served as a Global Technology & Operations executive, an international market-focused position leading teams in the United Kingdom, Asia and Latin America, and President, Consumer Products. Since April 2019, Ms. Desoer has served as Chair of Citibank, N.A. and as a member of the Board of Directors of Citigroup Inc. . - Barbara J. Desoer，自2015年10月起担任公司董事。Desoer现任Citibank, N.A（Citigroup Inc. 一家全资子公司，一家多元全球金融服务公司）首席执行官和董事，自2014年4月起担任该职位。Desoer之前从2013年10月到2014年4月担任Citibank, N.A首席运营官。除了担任首席执行官之外，Desoer还领导Citigroup的综合资本分析和评估过程。加入Citibank之前，Desoer在Bank of America（一家多元全球金融服务公司）任职了35年，最近的职位是担任Bank of America Home Loans总裁，领导Countrywide（美国最大的抵押贷款发起人和服务商）的整合。在Bank of America任职之前，Desoer担任全球技术&运营主管（一个国际市场支持职位，领导英国、亚洲和拉丁美洲的小组）。她还曾担任消费产品总裁。她现任the California大学at Berkeley客座董事。Desoer还曾担任多个非盈利和私人控股公司董事。
- Barbara J. Desoer,served as the CEO and a member of the Board of Directors of Citibank, N.A., a wholly owned subsidiary of Citigroup, Inc., a diversified global financial services company, both positions she held from April 2014 through April 2019, and COO of Citibank, N.A. from October 2013 to April 2014. Prior to Citibank, N.A., Ms. Desoer spent 35 years at Bank of America, a diversified global financial services company, most recently as President, Bank of America Home Loans, where she led the integration of Countrywide, the largest mortgage originator and servicer in the United States. In previous Bank of America roles, Ms. Desoer served as a Global Technology & Operations executive, an international market-focused position leading teams in the United Kingdom, Asia and Latin America, and President, Consumer Products. Since April 2019, Ms. Desoer has served as Chair of Citibank, N.A. and as a member of the Board of Directors of Citigroup Inc. .
- Jason M. Hollar
-
Jason M. Hollar, Cardinal Health首席执行官（自2022年起）。Cardinal Health首席财务官（2020 - 2022）。Tenneco Inc.（全球汽车产品和服务公司）的执行副总裁兼首席财务官（2018 - 2020）。Tenneco Inc.高级财务副总裁（2017 - 2018）。西尔斯控股公司（Sears Holding Corporation），一家美国大型消费零售商的控股公司（Sears于2018年10月申请破产保护）。他还曾担任Delphi Automotive's powertrain systems division的公司财务总监和财务副总裁，负责监督欧洲、中东和非洲地区。在职业生涯早期，他曾在Navistar的发动机集团、南美业务以及公司财务规划和分析担任财务职位，责任越来越大。
Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Additionally, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018. - Jason M. Hollar, Cardinal Health首席执行官（自2022年起）。Cardinal Health首席财务官（2020 - 2022）。Tenneco Inc.（全球汽车产品和服务公司）的执行副总裁兼首席财务官（2018 - 2020）。Tenneco Inc.高级财务副总裁（2017 - 2018）。西尔斯控股公司（Sears Holding Corporation），一家美国大型消费零售商的控股公司（Sears于2018年10月申请破产保护）。他还曾担任Delphi Automotive's powertrain systems division的公司财务总监和财务副总裁，负责监督欧洲、中东和非洲地区。在职业生涯早期，他曾在Navistar的发动机集团、南美业务以及公司财务规划和分析担任财务职位，责任越来越大。
- Jason M. Hollar,has served as Chief Executive Officer since September 2022. From May 2020 through August 2022, Mr. Hollar served as Chief Financial Officer. Additionally, Mr. Hollar served as Chief Financial Officer of Sears Holding Corporation ("Sears") from October 2016 to April 2017. Sears filed for Chapter 11 bankruptcy in October 2018.
- Phyllis R. Yale
-
Phyllis R. Yale自2016年7月起担任DaVita Inc.的董事之一。Yale女士自2010年7月起担任Bain＆Company，Inc.的顾问合伙人。“ Bain”是一家全球管理咨询公司。Bain从1987年至2010年7月，是建立Bain医疗保健业务的领导者。耶鲁女士在Bain任职期间，与医疗保健付款人，医疗服务提供者和医疗设备公司合作，并经常为世界领先的私募股权公司就其在医疗保健领域的投资提供建议。她曾担任卫生保健领域多家公共和私人公司的董事会成员，目前担任马萨诸塞州Blue Cross Blue Shield董事会主席，该组织总部位于美国马萨诸塞州，是一家非营利性健康计划。波士顿耶鲁女士曾担任美国长期医疗保健服务提供商Kindred Healthcare，Inc.的董事会主席，从2010年1月至2018年7月，她是一家私人专科医院National Surgical Hospitals的董事。运营商，以及ValueOptions，Inc.的董事，ValueOptions，Inc.是一家专注于身心健康和康复的健康改善公司，于2014年与Beacon Health Strategies合并。
Phyllis R. Yale,has been an Advisory Partner with Bain & Company, Inc. ("Bain"), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and a leader in building Bain's healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world's leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol Myers Squibb Company, a global biopharmaceutical company. Ms. Yale previously served as Chair of the Blue Cross Blue Shield of Massachusetts ("BCBS") Board of Directors from 2014 to 2019 and served on the board of BCBS from 2014 through December 2024, and as Chair of the Board of Directors of Kindred Healthcare, Inc. from 2010 to 2018. - Phyllis R. Yale自2016年7月起担任DaVita Inc.的董事之一。Yale女士自2010年7月起担任Bain＆Company，Inc.的顾问合伙人。“ Bain”是一家全球管理咨询公司。Bain从1987年至2010年7月，是建立Bain医疗保健业务的领导者。耶鲁女士在Bain任职期间，与医疗保健付款人，医疗服务提供者和医疗设备公司合作，并经常为世界领先的私募股权公司就其在医疗保健领域的投资提供建议。她曾担任卫生保健领域多家公共和私人公司的董事会成员，目前担任马萨诸塞州Blue Cross Blue Shield董事会主席，该组织总部位于美国马萨诸塞州，是一家非营利性健康计划。波士顿耶鲁女士曾担任美国长期医疗保健服务提供商Kindred Healthcare，Inc.的董事会主席，从2010年1月至2018年7月，她是一家私人专科医院National Surgical Hospitals的董事。运营商，以及ValueOptions，Inc.的董事，ValueOptions，Inc.是一家专注于身心健康和康复的健康改善公司，于2014年与Beacon Health Strategies合并。
- Phyllis R. Yale,has been an Advisory Partner with Bain & Company, Inc. ("Bain"), a global management consulting firm, since July 2010. Ms. Yale was a Partner with Bain from 1987 to July 2010, and a leader in building Bain's healthcare practice. In her role at Bain, Ms. Yale works with healthcare payors, providers, and medical device companies, and frequently advises the world's leading private equity firms on their investments in the healthcare sector. She has served as a member of the board of directors of several public and private companies in the healthcare sector, and since November 2019 has served as a member of the Board of Directors of Bristol Myers Squibb Company, a global biopharmaceutical company. Ms. Yale previously served as Chair of the Blue Cross Blue Shield of Massachusetts ("BCBS") Board of Directors from 2014 to 2019 and served on the board of BCBS from 2014 through December 2024, and as Chair of the Board of Directors of Kindred Healthcare, Inc. from 2010 to 2018.
- Gregory J. Moore
-
Gregory J. Moore，自 2019 年以来一直担任微软公司“微软”的公司副总裁，是一家生产计算机软件、云计算服务、个人计算机和电子产品以及其他相关服务的跨国技术公司，他领导着微软公司的健康和生活科学研究和产品开发组合。在加入微软之前，Moore博士于 2016 年至 2019 年担任谷歌公司副总裁，微软公司是一家专门从事互联网相关产品和服务的跨国科技公司，并且是全球谷歌云医疗保健和生命科学的创始人和领导者。 Moore 博士是一名工程师、执业医师和经验丰富的教育家。他在诊断放射学、神经放射学和临床信息学方面获得了委员会认证。在担任 Microsoft 和 Google 的领导职务之前，Moore 博士曾担任地区医疗保健提供商 Geisinger Health System 的首席新兴技术和信息学官，同时他还担任高级应用研究所所长。他之前的学术和临床任命包括斯坦福大学医学院、宾夕法尼亚州立大学医学院和韦恩州立大学医学院。从 2019 年到 2021 年与 Baxter International Inc. 合并，Moore 博士一直是医疗技术提供商 Hill-Rom Holdings, Inc. 的董事会成员。
Gregory J. Moore,served as Corporate Vice President for Microsoft Health and Life Sciences, a division of Microsoft Corporation ("Microsoft"), a multinational technology company that produces computer software, cloud computing services, personal computers and electronics, and other related services, from 2019 to 2023, where he led Microsoft's health and life sciences research and artificial intelligence ("AI") and cloud product development portfolio. Prior to Microsoft, Dr. Moore served as Vice President of Google Inc. ("Google"), a multinational technology company that specializes in Internet-related products and services, from 2016 to 2019, and was the founder and leader of Google Cloud Healthcare and Life Sciences globally. Dr. Moore is an engineer, practicing physician, and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, a regional healthcare provider, where he was also Director of the Institute of Advanced Application. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. In February 2025, Dr. Moore was appointed as a member of the Board of Directors of Fortive Corporation, a provider of essential technologies for connected workflow solutions. From 2023 to 2024, Dr. Moore served as a member of the Board of Directors of Olink Holding AB, a biotechnology company focused on proteomics, until its merger with Thermo Fisher Scientific Inc., and from 2019 to 2021, Dr. Moore served as a director of Hill-Rom Holdings, Inc., a medical technology provider, until its merger with Baxter International Inc. In 2024, Dr. Moore earned the National Association of Corporate Directors ("NACD") CERT Certificate in Cyber-Risk Oversight. - Gregory J. Moore，自 2019 年以来一直担任微软公司“微软”的公司副总裁，是一家生产计算机软件、云计算服务、个人计算机和电子产品以及其他相关服务的跨国技术公司，他领导着微软公司的健康和生活科学研究和产品开发组合。在加入微软之前，Moore博士于 2016 年至 2019 年担任谷歌公司副总裁，微软公司是一家专门从事互联网相关产品和服务的跨国科技公司，并且是全球谷歌云医疗保健和生命科学的创始人和领导者。 Moore 博士是一名工程师、执业医师和经验丰富的教育家。他在诊断放射学、神经放射学和临床信息学方面获得了委员会认证。在担任 Microsoft 和 Google 的领导职务之前，Moore 博士曾担任地区医疗保健提供商 Geisinger Health System 的首席新兴技术和信息学官，同时他还担任高级应用研究所所长。他之前的学术和临床任命包括斯坦福大学医学院、宾夕法尼亚州立大学医学院和韦恩州立大学医学院。从 2019 年到 2021 年与 Baxter International Inc. 合并，Moore 博士一直是医疗技术提供商 Hill-Rom Holdings, Inc. 的董事会成员。
- Gregory J. Moore,served as Corporate Vice President for Microsoft Health and Life Sciences, a division of Microsoft Corporation ("Microsoft"), a multinational technology company that produces computer software, cloud computing services, personal computers and electronics, and other related services, from 2019 to 2023, where he led Microsoft's health and life sciences research and artificial intelligence ("AI") and cloud product development portfolio. Prior to Microsoft, Dr. Moore served as Vice President of Google Inc. ("Google"), a multinational technology company that specializes in Internet-related products and services, from 2016 to 2019, and was the founder and leader of Google Cloud Healthcare and Life Sciences globally. Dr. Moore is an engineer, practicing physician, and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the Chief Emerging Technology and Informatics Officer at Geisinger Health System, a regional healthcare provider, where he was also Director of the Institute of Advanced Application. His prior academic and clinical appointments include Stanford University School of Medicine, Penn State University College of Medicine, and Wayne State University School of Medicine. In February 2025, Dr. Moore was appointed as a member of the Board of Directors of Fortive Corporation, a provider of essential technologies for connected workflow solutions. From 2023 to 2024, Dr. Moore served as a member of the Board of Directors of Olink Holding AB, a biotechnology company focused on proteomics, until its merger with Thermo Fisher Scientific Inc., and from 2019 to 2021, Dr. Moore served as a director of Hill-Rom Holdings, Inc., a medical technology provider, until its merger with Baxter International Inc. In 2024, Dr. Moore earned the National Association of Corporate Directors ("NACD") CERT Certificate in Cyber-Risk Oversight.
- Wendy L. Schoppert
-
Wendy L. Schoppert，她于2020年7月加入Office Depot, Inc.的董事会。Schoppert女士拥有超过30年的多元化财务和运营领导经验，自2014年从Sleep Number Corporation退休以来一直担任专业董事。她曾担任Sleep Number的执行副总裁兼首席财务官（从2011年到2014年）。2011年5月以来，她担任Select Comfort的执行副总裁兼首席财务官，并与2013年宣布她将于2014年退休。她曾担任Sleep Number高级副总裁兼首席信息官（从2008年到2011年），以及国际和新渠道发展高级副总裁（从2005年到2008年）。加入Sleep Number之前，她曾领导U.S. Bank的私人资产管理团队，并于2002年至2005年担任U.S. Bank资产管理部的产品、营销和企业发展部主管。Schoppert女士的职业生涯始于航空行业，在美国航空公司（American Airlines）、西北航空公司（Northwest Airlines）和美国西部航空公司（America West Airlines）担任各种财务、战略和综合管理领导职位，并担任越来越多的角色和责任。Schoppert女士是Bremer Financial Corporation（一家总部位于明尼苏达州的金融服务公司）的董事，并担任其审计委员会主席和薪酬委员会成员。Schoppert女士还担任非营利和专业组织的成员。Big Lots，康奈尔大学数学与运筹学学士，康奈尔大学金融与综合管理工商管理硕士学位（2015年5月）。
Wendy L. Schoppert was appointed to the Board in May 2025, and she is currently a member of the Company's Audit Committee. Ms. Schoppert served as Executive Vice President and Chief Financial Officer of Sleep Number Corporation from 2011 to 2014. During her tenure at Sleep Number, Ms. Schoppert also served as Senior Vice President and Chief Information Officer from 2008 to 2011 and Senior Vice President, International and New Channel Development from 2005 to 2008. Prior to joining Sleep Number, Ms. Schoppert led U.S. Bank's Private Asset Management team and served as Head of Product, Marketing & Corporate Development for U.S. Bank's Asset Management division from 2002 to 2005. Ms. Schoppert began her career in the airline indtry, serving in vario financial, strategic and general management leadership positions at American Airlines, Northst Airlines and America st Airlines. - Wendy L. Schoppert，她于2020年7月加入Office Depot, Inc.的董事会。Schoppert女士拥有超过30年的多元化财务和运营领导经验，自2014年从Sleep Number Corporation退休以来一直担任专业董事。她曾担任Sleep Number的执行副总裁兼首席财务官（从2011年到2014年）。2011年5月以来，她担任Select Comfort的执行副总裁兼首席财务官，并与2013年宣布她将于2014年退休。她曾担任Sleep Number高级副总裁兼首席信息官（从2008年到2011年），以及国际和新渠道发展高级副总裁（从2005年到2008年）。加入Sleep Number之前，她曾领导U.S. Bank的私人资产管理团队，并于2002年至2005年担任U.S. Bank资产管理部的产品、营销和企业发展部主管。Schoppert女士的职业生涯始于航空行业，在美国航空公司（American Airlines）、西北航空公司（Northwest Airlines）和美国西部航空公司（America West Airlines）担任各种财务、战略和综合管理领导职位，并担任越来越多的角色和责任。Schoppert女士是Bremer Financial Corporation（一家总部位于明尼苏达州的金融服务公司）的董事，并担任其审计委员会主席和薪酬委员会成员。Schoppert女士还担任非营利和专业组织的成员。Big Lots，康奈尔大学数学与运筹学学士，康奈尔大学金融与综合管理工商管理硕士学位（2015年5月）。
- Wendy L. Schoppert was appointed to the Board in May 2025, and she is currently a member of the Company's Audit Committee. Ms. Schoppert served as Executive Vice President and Chief Financial Officer of Sleep Number Corporation from 2011 to 2014. During her tenure at Sleep Number, Ms. Schoppert also served as Senior Vice President and Chief Information Officer from 2008 to 2011 and Senior Vice President, International and New Channel Development from 2005 to 2008. Prior to joining Sleep Number, Ms. Schoppert led U.S. Bank's Private Asset Management team and served as Head of Product, Marketing & Corporate Development for U.S. Bank's Asset Management division from 2002 to 2005. Ms. Schoppert began her career in the airline indtry, serving in vario financial, strategic and general management leadership positions at American Airlines, Northst Airlines and America st Airlines.
- Dennis W. Pullin
-
Dennis W. Pullin，自2017年起担任Virtua Health（“Virtua”）的总裁兼首席执行官。从2009年到2017年，普林先生担任MedStar Harbor Hospital的总裁，这是一家位于美国中大西洋地区的非营利性社区医疗保健组织。从2006年到2009年，普林先生担任位于华盛顿特区的最大私立教学和研究医院MedStar华盛顿医院中心的首席运营官和高级副总裁。Pullin先生曾于2002年至2006年在德州医疗中心的三级社区教学医院CHI St. Luke's Health担任运营和业务发展副总裁。自2021年5月起，Pullin先生担任全球多元化产业公司Hillenbrand, Inc.的董事会成员。
Dennis W. Pullin,has served as President and CEO of Virtua Health ("Virtua"), an academic health system in New Jersey offering a range of preventative, primary, ambulatory, acute and tertiary care since 2017. From 2009 to 2017, Mr. Pullin served as President of MedStar Harbor Hospital, a not-for-profit, community-based health care organization in the U.S. Mid-Atlantic region. From 2006 to 2009, Mr. Pullin served as Chief Operating Officer and Senior Vice President of MedStar Washington Hospital Center, the largest private teaching and research hospital based in Washington, D.C. Mr. Pullin served as Vice President of Operations and Business Development at CHI St. Luke's Health, a tertiary community teaching hospital in the Texas Medical Center from 2002 to 2006. Since May 2021, Mr. Pullin has served as a member of the Board of Directors of Hillenbrand, Inc., a global diversified industrial company. - Dennis W. Pullin，自2017年起担任Virtua Health（“Virtua”）的总裁兼首席执行官。从2009年到2017年，普林先生担任MedStar Harbor Hospital的总裁，这是一家位于美国中大西洋地区的非营利性社区医疗保健组织。从2006年到2009年，普林先生担任位于华盛顿特区的最大私立教学和研究医院MedStar华盛顿医院中心的首席运营官和高级副总裁。Pullin先生曾于2002年至2006年在德州医疗中心的三级社区教学医院CHI St. Luke's Health担任运营和业务发展副总裁。自2021年5月起，Pullin先生担任全球多元化产业公司Hillenbrand, Inc.的董事会成员。
- Dennis W. Pullin,has served as President and CEO of Virtua Health ("Virtua"), an academic health system in New Jersey offering a range of preventative, primary, ambulatory, acute and tertiary care since 2017. From 2009 to 2017, Mr. Pullin served as President of MedStar Harbor Hospital, a not-for-profit, community-based health care organization in the U.S. Mid-Atlantic region. From 2006 to 2009, Mr. Pullin served as Chief Operating Officer and Senior Vice President of MedStar Washington Hospital Center, the largest private teaching and research hospital based in Washington, D.C. Mr. Pullin served as Vice President of Operations and Business Development at CHI St. Luke's Health, a tertiary community teaching hospital in the Texas Medical Center from 2002 to 2006. Since May 2021, Mr. Pullin has served as a member of the Board of Directors of Hillenbrand, Inc., a global diversified industrial company.
- Pamela M. Arway
-
Pamela M. Arway，2010年5月起担任Hershey董事。她是治理委员会主席，并且是审计委员会和执行委员会成员。此前她曾在位于纽约的美国运通公司（一家全球支付、网络和旅行公司）及其子公司担任各种职位。2005年10月至2008年1月期间曾担任美国运通国际有限公司新加坡公司总裁，负责日本/亚太/澳大利亚地区业务；2004年12月至2005年10月期间担任位于澳大利亚悉尼的美国运通澳大利亚有限公司CEO；2000年7月至2004年12月期间，她曾担任美国运通公司执行副总裁和总经理，负责北美地区公司传送业务。她在美国运通公司工作的21年期间，她拥有了金融、市场、国际业务、政府事务、消费品和人力资源方面的经验。2009年7月起担任DaVita HealthCare Partners, Inc.董事。她拥有纽芬兰纪念大学语言学学士学位和加拿大安大略金斯顿皇后大学工商管理硕士学位。
Pamela M. Arway,served as the President of the Japan, Asia-Pacific, Australia region for American Express International, Inc., a global payment services and travel company, from 2005 to 2008. Ms. Arway joined the American Express Company in 1987, and subsequently served in various capacities, including as Chief Executive Officer ("CEO") of American Express Australia Limited from 2004 to 2005 and as Executive Vice President of Corporate Travel, North America from 2000 to 2004. Prior to her retirement in October 2008, she also served as advisor to the American Express Company's Chairman and CEO. Ms. Arway has been a member of the Board of Directors of Iron Mountain Incorporated, an enterprise information management services company ("Iron Mountain"), since March 2014, serving as Independent Chairperson of Iron Mountain's Board since 2022, and served as a member of the Board of Directors of The Hershey Company, a chocolate and confectionery company, from 2010 to 2024. - Pamela M. Arway，2010年5月起担任Hershey董事。她是治理委员会主席，并且是审计委员会和执行委员会成员。此前她曾在位于纽约的美国运通公司（一家全球支付、网络和旅行公司）及其子公司担任各种职位。2005年10月至2008年1月期间曾担任美国运通国际有限公司新加坡公司总裁，负责日本/亚太/澳大利亚地区业务；2004年12月至2005年10月期间担任位于澳大利亚悉尼的美国运通澳大利亚有限公司CEO；2000年7月至2004年12月期间，她曾担任美国运通公司执行副总裁和总经理，负责北美地区公司传送业务。她在美国运通公司工作的21年期间，她拥有了金融、市场、国际业务、政府事务、消费品和人力资源方面的经验。2009年7月起担任DaVita HealthCare Partners, Inc.董事。她拥有纽芬兰纪念大学语言学学士学位和加拿大安大略金斯顿皇后大学工商管理硕士学位。
- Pamela M. Arway,served as the President of the Japan, Asia-Pacific, Australia region for American Express International, Inc., a global payment services and travel company, from 2005 to 2008. Ms. Arway joined the American Express Company in 1987, and subsequently served in various capacities, including as Chief Executive Officer ("CEO") of American Express Australia Limited from 2004 to 2005 and as Executive Vice President of Corporate Travel, North America from 2000 to 2004. Prior to her retirement in October 2008, she also served as advisor to the American Express Company's Chairman and CEO. Ms. Arway has been a member of the Board of Directors of Iron Mountain Incorporated, an enterprise information management services company ("Iron Mountain"), since March 2014, serving as Independent Chairperson of Iron Mountain's Board since 2022, and served as a member of the Board of Directors of The Hershey Company, a chocolate and confectionery company, from 2010 to 2024.
- Adam H. Schechter
-
Adam H. Schechter自2013年4月1日起担任公司董事，自2019年11月1日起担任公司总裁兼首席执行官。在此之前，Schechter先生是默克公司的执行副总裁， 从2010年到2018年，他是默克公司执行委员会以及药品和疫苗运营委员会的成员。 他于2019年1月至2019年7月担任默克（Merck）首席执行官的特别顾问。他曾担任默克（Merck）全球人类健康部总裁，该部门于2010年至2018年包括该公司的全球制药和疫苗业务。 Schechter先生于2007年至2010年担任全球制药业务总裁。
Adam H. Schechter,has served as a director of the Company since April 2013, President and Chief Executive Officer of the Company since November 2019, and Chairman of the Board since May 2020. Prior to that, Mr. Schechter was President of Global Human Health and an Executive Vice President of Merck & Co., Inc., a pharmaceutical company, from 2010 to 2018, where he was a member of Merck's executive committee. He served as special advisor to the CEO of Merck from January 2019 to July 2019. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter holds a bachelor's degree in biology from La Salle University. - Adam H. Schechter自2013年4月1日起担任公司董事，自2019年11月1日起担任公司总裁兼首席执行官。在此之前，Schechter先生是默克公司的执行副总裁， 从2010年到2018年，他是默克公司执行委员会以及药品和疫苗运营委员会的成员。 他于2019年1月至2019年7月担任默克（Merck）首席执行官的特别顾问。他曾担任默克（Merck）全球人类健康部总裁，该部门于2010年至2018年包括该公司的全球制药和疫苗业务。 Schechter先生于2007年至2010年担任全球制药业务总裁。
- Adam H. Schechter,has served as a director of the Company since April 2013, President and Chief Executive Officer of the Company since November 2019, and Chairman of the Board since May 2020. Prior to that, Mr. Schechter was President of Global Human Health and an Executive Vice President of Merck & Co., Inc., a pharmaceutical company, from 2010 to 2018, where he was a member of Merck's executive committee. He served as special advisor to the CEO of Merck from January 2019 to July 2019. Prior to becoming President, Global Human Health, Mr. Schechter served as President, Global Pharmaceutical Business from 2007 to 2010. Mr. Schechter holds a bachelor's degree in biology from La Salle University.
高管简历
中英对照 | 中文 | 英文- Javier J. Rodriguez
Javier J. Rodriguez，曾担任Davita Inc.的董事。自2019年6月起担任首席执行官。从2014年3月到2019年6月，他担任DaVita Kidney Care的首席执行官。自1998年加入公司以来，他曾担任多个不同的职务。2012年2月至2014年3月，他担任Davita Inc.的董事。从2006年4月到2012年2月，他担任Davita Inc.的董事，高级副总裁。从2000年到2006年，他担任运营和付款合同副总裁。Rodriguez先生于1998年加入公司，担任价值管理董事。在加入公司之前，他从1995年到1996年在Baxter Healthcare Corporation的财务部门工作。他还曾担任Mexico City CBS Marketing Inc.的运营总监。自2020年6月以来，Rodriguez先生一直是Gilead Sciences, Inc.（一家研究型制药公司）的董事会成员。
Javier J. Rodriguez,joined Board in June 2020.Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout 12 countries.He assumed his current role in 2019, building on his more than 20 years of increasing company leadership and commitment to transforming care delivery to improve quality of life for patients with kidney disease – from the earliest stages through transplantation.From 2014 to 2019, he was the CEO of DaVita Kidney Care, the company's business unit that treats patients with kidney failure and end-stage kidney disease.Mr. Rodriguez is recognized for his vision and leadership in transforming how kidney care is delivered and accelerating the digital transformation to improve patients' lives while lowering costs for the health care system.He currently serves on the board of directors of DaVita, Inc.- Javier J. Rodriguez，曾担任Davita Inc.的董事。自2019年6月起担任首席执行官。从2014年3月到2019年6月，他担任DaVita Kidney Care的首席执行官。自1998年加入公司以来，他曾担任多个不同的职务。2012年2月至2014年3月，他担任Davita Inc.的董事。从2006年4月到2012年2月，他担任Davita Inc.的董事，高级副总裁。从2000年到2006年，他担任运营和付款合同副总裁。Rodriguez先生于1998年加入公司，担任价值管理董事。在加入公司之前，他从1995年到1996年在Baxter Healthcare Corporation的财务部门工作。他还曾担任Mexico City CBS Marketing Inc.的运营总监。自2020年6月以来，Rodriguez先生一直是Gilead Sciences, Inc.（一家研究型制药公司）的董事会成员。
- Javier J. Rodriguez,joined Board in June 2020.Mr. Rodriguez is the Chief Executive Officer of DaVita Inc., a Fortune 500 company providing healthcare services to kidney disease patients throughout 12 countries.He assumed his current role in 2019, building on his more than 20 years of increasing company leadership and commitment to transforming care delivery to improve quality of life for patients with kidney disease – from the earliest stages through transplantation.From 2014 to 2019, he was the CEO of DaVita Kidney Care, the company's business unit that treats patients with kidney failure and end-stage kidney disease.Mr. Rodriguez is recognized for his vision and leadership in transforming how kidney care is delivered and accelerating the digital transformation to improve patients' lives while lowering costs for the health care system.He currently serves on the board of directors of DaVita, Inc.
- Kathleen A. Waters
Kathleen A. Waters，成为Davita Inc.2016年5月担任CLO，监督企业的所有法律和监管职能。2021年2月，Waters女士成为Davita Inc.。作为首席法律和公共事务官，她还承担了联邦政府事务的责任。加入公司之前，她曾担任Health Net, Inc.（上市的管理式医疗组织）的高级副总裁、总法律顾问兼秘书（2015年至2016年）。加入Health Net公司之前，Waters女士从2003年到2015年担任Morgan, Lewis & Bockius LLP的诉讼业务合伙人，在那里她是医疗保健集团的联合主席。在加入Morgan Lewis之前，Waters女士自1994年起在多家律师事务所从事私人执业。
Kathleen A. Waters,became Chief Legal Officer in May 2016, overseeing all legal and regulatory functions for the enterprise. Ms. Waters became Chief Legal and Public Affairs Officer as she also took over responsibility for federal government affairs in February 2021 and state government affairs in September 2024. Prior to joining the Company, Ms. Waters was Senior Vice President, General Counsel and Secretary of Health Net, Inc., a publicly traded managed care organization, from 2015 to 2016. Prior to Health Net, Inc., Ms. Waters was a Partner in Morgan, Lewis & Bockius LLP's litigation practice from 2003 to 2015, where she served, among other roles, as the co-chair of the healthcare group. Prior to Morgan Lewis, Ms. Waters was in private practice at various law firms since 1994.- Kathleen A. Waters，成为Davita Inc.2016年5月担任CLO，监督企业的所有法律和监管职能。2021年2月，Waters女士成为Davita Inc.。作为首席法律和公共事务官，她还承担了联邦政府事务的责任。加入公司之前，她曾担任Health Net, Inc.（上市的管理式医疗组织）的高级副总裁、总法律顾问兼秘书（2015年至2016年）。加入Health Net公司之前，Waters女士从2003年到2015年担任Morgan, Lewis & Bockius LLP的诉讼业务合伙人，在那里她是医疗保健集团的联合主席。在加入Morgan Lewis之前，Waters女士自1994年起在多家律师事务所从事私人执业。
- Kathleen A. Waters,became Chief Legal Officer in May 2016, overseeing all legal and regulatory functions for the enterprise. Ms. Waters became Chief Legal and Public Affairs Officer as she also took over responsibility for federal government affairs in February 2021 and state government affairs in September 2024. Prior to joining the Company, Ms. Waters was Senior Vice President, General Counsel and Secretary of Health Net, Inc., a publicly traded managed care organization, from 2015 to 2016. Prior to Health Net, Inc., Ms. Waters was a Partner in Morgan, Lewis & Bockius LLP's litigation practice from 2003 to 2015, where she served, among other roles, as the co-chair of the healthcare group. Prior to Morgan Lewis, Ms. Waters was in private practice at various law firms since 1994.
- James O. Hearty
James O. Hearty，于2018年3月成为DAVITA INC.的CCO.2015年9月至2018年3月，他担任DAVITA INC.高级副总裁兼肾脏护理首席执行官，在此之前，2012年2月至2015年8月，他曾担任副总裁兼副总法律顾问。在加入DAVITA INC.之前，他曾在美国司法部（“DOJ”）担任检察官和审判律师14年。他开始于华盛顿特区司法部民事司，四年后成为科罗拉多州U.S. Attorney's Office的助理美国检察官。Hearty先生曾在U.S. Attorney's Office担任过多个领导职位，包括刑事司副司长。Hearty先生也是Urban Peak的董事会成员，这是一家Denver non-profit，为无家可归的年轻人提供服务。
James O. Hearty,became enterprise CCO in March 2018. From September 2015 to March 2018, he served as Senior Vice President and CCO - Kidney Care, and, prior to that, from February 2012 to August 2015, he served as Vice President, Associate General Counsel. Prior to joining DaVita, he was a prosecutor and trial attorney with the U.S. Department of Justice ("DOJ") for 14 years. He started in the Civil Division of the DOJ in Washington D.C. and four years later became an Assistant U.S. Attorney in the U.S. Attorney's Office for the District of Colorado. Mr. Hearty held several leadership positions at the U.S. Attorney's Office, including Deputy Chief of the criminal division. Mr. Hearty also serves on the board of Urban Peak, a Denver non-profit that serves youth experiencing homelessness.- James O. Hearty，于2018年3月成为DAVITA INC.的CCO.2015年9月至2018年3月，他担任DAVITA INC.高级副总裁兼肾脏护理首席执行官，在此之前，2012年2月至2015年8月，他曾担任副总裁兼副总法律顾问。在加入DAVITA INC.之前，他曾在美国司法部（“DOJ”）担任检察官和审判律师14年。他开始于华盛顿特区司法部民事司，四年后成为科罗拉多州U.S. Attorney's Office的助理美国检察官。Hearty先生曾在U.S. Attorney's Office担任过多个领导职位，包括刑事司副司长。Hearty先生也是Urban Peak的董事会成员，这是一家Denver non-profit，为无家可归的年轻人提供服务。
- James O. Hearty,became enterprise CCO in March 2018. From September 2015 to March 2018, he served as Senior Vice President and CCO - Kidney Care, and, prior to that, from February 2012 to August 2015, he served as Vice President, Associate General Counsel. Prior to joining DaVita, he was a prosecutor and trial attorney with the U.S. Department of Justice ("DOJ") for 14 years. He started in the Civil Division of the DOJ in Washington D.C. and four years later became an Assistant U.S. Attorney in the U.S. Attorney's Office for the District of Colorado. Mr. Hearty held several leadership positions at the U.S. Attorney's Office, including Deputy Chief of the criminal division. Mr. Hearty also serves on the board of Urban Peak, a Denver non-profit that serves youth experiencing homelessness.
- Christopher Berry
Christopher Berry，于2023年8月加入DaVita，担任集团会计副总裁，并成为DaVita Inc.。2023年9月。从2022年8月到2023年8月，他担任Sonder Holdings Inc.（“Sonder”）的高级副总裁兼首席运营官，这是一家上市的酒店公司。他还曾担任Sonder的临时首席财务官（从2023年1月到2023年3月）。在加入Sonder之前，Berry先生在Alaska Air Group, Inc.（一家上市的航空控股公司）担任各种职务，从2017年2月到2022年4月担任副总裁、公司财务总监和CAO，从2014年2月到2017年2月担任会计总经理、公司财务总监和首席会计官，从2010年10月到2014年2月担任投资者关系总经理，从2005年3月到2010年10月担任财务报告和会计总监。
Christopher Berry,joined DaVita as Group Vice President, Accounting in August 2023 and became Davita Inc. CAO in September 2023. Mr. Berry was the Senior Vice President and CAO at Sonder Holdings Inc. ("Sonder"), a publicly traded hospitality company, from August 2022 to August 2023. He also previously served as Sonder's Interim Principal Financial Officer from January 2023 to March 2023. Prior to joining Sonder, Mr. Berry held various roles at Alaska Air Group, Inc., a publicly traded airline holding company, serving as Vice President, Corporate Controller, and CAO from February 2017 to April 2022, Managing Director of Accounting, Corporate Controller and Principal Accounting Officer from February 2014 to February 2017, Managing Director, Investor Relations from October 2010 to February 2014, and Director, Financial Reporting and Accounting from March 2005 to October 2010.- Christopher Berry，于2023年8月加入DaVita，担任集团会计副总裁，并成为DaVita Inc.。2023年9月。从2022年8月到2023年8月，他担任Sonder Holdings Inc.（“Sonder”）的高级副总裁兼首席运营官，这是一家上市的酒店公司。他还曾担任Sonder的临时首席财务官（从2023年1月到2023年3月）。在加入Sonder之前，Berry先生在Alaska Air Group, Inc.（一家上市的航空控股公司）担任各种职务，从2017年2月到2022年4月担任副总裁、公司财务总监和CAO，从2014年2月到2017年2月担任会计总经理、公司财务总监和首席会计官，从2010年10月到2014年2月担任投资者关系总经理，从2005年3月到2010年10月担任财务报告和会计总监。
- Christopher Berry,joined DaVita as Group Vice President, Accounting in August 2023 and became Davita Inc. CAO in September 2023. Mr. Berry was the Senior Vice President and CAO at Sonder Holdings Inc. ("Sonder"), a publicly traded hospitality company, from August 2022 to August 2023. He also previously served as Sonder's Interim Principal Financial Officer from January 2023 to March 2023. Prior to joining Sonder, Mr. Berry held various roles at Alaska Air Group, Inc., a publicly traded airline holding company, serving as Vice President, Corporate Controller, and CAO from February 2017 to April 2022, Managing Director of Accounting, Corporate Controller and Principal Accounting Officer from February 2014 to February 2017, Managing Director, Investor Relations from October 2010 to February 2014, and Director, Financial Reporting and Accounting from March 2005 to October 2010.
- David P. Maughan
David P. Maughan，从2019年11月至2024年9月担任肾脏护理高级副总裁，负责DaVita的全国家庭和医院服务业务，以及一系列关键业务职能，包括人力资源，IT，营销和通信以及州政府事务的监督。他于2006年加入DaVita，并于2006年9月至2019年11月担任各种现场运营职务。加入DaVita之前，2001年至2004年，他在纽约和伦敦的Goldman Sachs工作。他在杨百翰大学（Brigham Young University）获得英语文学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
David P. Maughan,became COO, DaVita Kidney Care in September 2024. Prior to this role, Mr. Maughan served as Senior Vice President of DaVita Kidney Care, from November 2019 to September 2024, with expansive responsibilities including oversight of Hospital Services and national Home businesses as well as a range of key business functions, such as human resources, talent strategy, IT, state government affairs, marketing and communications. Since joining the company in 2006, Mr. Maughan has served in a number of leadership roles with increasing operational responsibilities. Prior to joining DaVita, he worked at Goldman Sachs in both New York City and London. Mr. Maughan received his undergraduate degree from Brigham Young University and received his MBA from the Harvard Business School.- David P. Maughan，从2019年11月至2024年9月担任肾脏护理高级副总裁，负责DaVita的全国家庭和医院服务业务，以及一系列关键业务职能，包括人力资源，IT，营销和通信以及州政府事务的监督。他于2006年加入DaVita，并于2006年9月至2019年11月担任各种现场运营职务。加入DaVita之前，2001年至2004年，他在纽约和伦敦的Goldman Sachs工作。他在杨百翰大学（Brigham Young University）获得英语文学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- David P. Maughan,became COO, DaVita Kidney Care in September 2024. Prior to this role, Mr. Maughan served as Senior Vice President of DaVita Kidney Care, from November 2019 to September 2024, with expansive responsibilities including oversight of Hospital Services and national Home businesses as well as a range of key business functions, such as human resources, talent strategy, IT, state government affairs, marketing and communications. Since joining the company in 2006, Mr. Maughan has served in a number of leadership roles with increasing operational responsibilities. Prior to joining DaVita, he worked at Goldman Sachs in both New York City and London. Mr. Maughan received his undergraduate degree from Brigham Young University and received his MBA from the Harvard Business School.
- Joel Ackerman
Joel Ackerman成为了Davita公司首席财务官，2017年2月。自2019年4月起，Ackerman先生还被任命为Davita Inc.的董事，财务主管。在加入Davita Inc.之前，他曾担任Champions Oncology, Inc.（一家上市公司，从事先进技术解决方案和服务的开发，以个性化肿瘤药物的开发和Davita Inc. e）的首席执行官兼董事会成员（2010年10月以来）。他目前是Champions Oncology的董事会主席。1999年1月至2008年9月，他担任全球私募股权公司Warburg Pincus的董事总经理，在那里他领导医疗保健服务团队近10年。2008年12月至2018年7月，他担任Kindred Healthcare, Inc.（医疗保健服务公司）的董事会成员；1999年9月至2013年5月被Aetna Inc.收购，他担任Coventry Health Care, Inc.（国家管理医疗公司）的董事会成员。他也是One Acre Fund的董事会成员，这是一家专注于小农农业的非营利组织，为非洲300多万自给自足的农民提供服务。
Joel Ackerman,will transition to Director of the Company on August 25, 2025. He served as the Chairman of the Board of the Company from January 2017 until August 25, 2025. Previously, Mr. Ackerman served as Chief Executive Officer and a director of the Company from October 2010 to January 2017. Mr Ackerman is currently the Chief Financial Officer of Davita, Inc. Mr. Ackerman received a bachelor's degree from Columbia University, where he graduated summa cum laude in 1988, and a master's degree in Physics from Harvard University in 1990. From 1990 to 1993, Mr. Ackerman was an associate with Mercer Management Consulting, a global strategy consulting firm. From 1993 to 2008, Mr. Ackerman was employed by Warburg Pincus, LLC, a global private equity investment firm. There, Mr. Ackerman served in various capacities including Managing Director, Head of Healthcare Services, and as a member of the firm's executive management team. During 2010, Mr. Ackerman served as a senior portfolio fellow with Acumen Fund, a non-profit global venture fund that Champions Oncology, Inc. es entrepreneurial approaches to address global poverty.- Joel Ackerman成为了Davita公司首席财务官，2017年2月。自2019年4月起，Ackerman先生还被任命为Davita Inc.的董事，财务主管。在加入Davita Inc.之前，他曾担任Champions Oncology, Inc.（一家上市公司，从事先进技术解决方案和服务的开发，以个性化肿瘤药物的开发和Davita Inc. e）的首席执行官兼董事会成员（2010年10月以来）。他目前是Champions Oncology的董事会主席。1999年1月至2008年9月，他担任全球私募股权公司Warburg Pincus的董事总经理，在那里他领导医疗保健服务团队近10年。2008年12月至2018年7月，他担任Kindred Healthcare, Inc.（医疗保健服务公司）的董事会成员；1999年9月至2013年5月被Aetna Inc.收购，他担任Coventry Health Care, Inc.（国家管理医疗公司）的董事会成员。他也是One Acre Fund的董事会成员，这是一家专注于小农农业的非营利组织，为非洲300多万自给自足的农民提供服务。
- Joel Ackerman,will transition to Director of the Company on August 25, 2025. He served as the Chairman of the Board of the Company from January 2017 until August 25, 2025. Previously, Mr. Ackerman served as Chief Executive Officer and a director of the Company from October 2010 to January 2017. Mr Ackerman is currently the Chief Financial Officer of Davita, Inc. Mr. Ackerman received a bachelor's degree from Columbia University, where he graduated summa cum laude in 1988, and a master's degree in Physics from Harvard University in 1990. From 1990 to 1993, Mr. Ackerman was an associate with Mercer Management Consulting, a global strategy consulting firm. From 1993 to 2008, Mr. Ackerman was employed by Warburg Pincus, LLC, a global private equity investment firm. There, Mr. Ackerman served in various capacities including Managing Director, Head of Healthcare Services, and as a member of the firm's executive management team. During 2010, Mr. Ackerman served as a senior portfolio fellow with Acumen Fund, a non-profit global venture fund that Champions Oncology, Inc. es entrepreneurial approaches to address global poverty.